271 related articles for article (PubMed ID: 10022870)
1. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
Du W; Lebowitz PF; Prendergast GC
Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB.
Lebowitz PF; Casey PJ; Prendergast GC; Thissen JA
J Biol Chem; 1997 Jun; 272(25):15591-4. PubMed ID: 9188444
[TBL] [Abstract][Full Text] [Related]
3. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
Zeng PY; Rane N; Du W; Chintapalli J; Prendergast GC
Oncogene; 2003 Feb; 22(8):1124-34. PubMed ID: 12606940
[TBL] [Abstract][Full Text] [Related]
4. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
Du W; Prendergast GC
Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
[TBL] [Abstract][Full Text] [Related]
5. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
[TBL] [Abstract][Full Text] [Related]
6. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
7. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
8. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
[TBL] [Abstract][Full Text] [Related]
9. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB.
Kamasani U; Liu AX; Prendergast GC
Cancer Biol Ther; 2003; 2(3):273-80. PubMed ID: 12878865
[TBL] [Abstract][Full Text] [Related]
10. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
van Golen KL; Bao L; DiVito MM; Wu Z; Prendergast GC; Merajver SD
Mol Cancer Ther; 2002 Jun; 1(8):575-83. PubMed ID: 12479217
[TBL] [Abstract][Full Text] [Related]
11. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.
Lebowitz PF; Davide JP; Prendergast GC
Mol Cell Biol; 1995 Dec; 15(12):6613-22. PubMed ID: 8524226
[TBL] [Abstract][Full Text] [Related]
12. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors.
Liu A; Prendergast GC
FEBS Lett; 2000 Sep; 481(3):205-8. PubMed ID: 11007964
[TBL] [Abstract][Full Text] [Related]
13. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase.
Wherlock M; Gampel A; Futter C; Mellor H
J Cell Sci; 2004 Jul; 117(Pt 15):3221-31. PubMed ID: 15226397
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
18. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition.
Kamasani U; Huang M; Duhadaway JB; Prochownik EV; Donover PS; Prendergast GC
Cancer Res; 2004 Nov; 64(22):8389-96. PubMed ID: 15548709
[TBL] [Abstract][Full Text] [Related]
19. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.
Kim HS; Kim JW; Gang J; Wen J; Koh SS; Koh JS; Chung HH; Song SY
Toxicol Appl Pharmacol; 2006 Sep; 215(3):317-29. PubMed ID: 16712893
[TBL] [Abstract][Full Text] [Related]
20. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.
Allal C; Pradines A; Hamilton AD; Sebti SM; Favre G
Cell Cycle; 2002; 1(6):430-7. PubMed ID: 12548020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
